INS and Hypoglycemia: Depending on our comparison between URAIs and standard insulin, individualized treatment selection is crucial; Despite offering improved glycemic stability and reduced hypoglycemia, the cost appears to be an increase in infusion site reactions, necessitating careful risk-benefit assessment.